Finance

Beta
Lists
IMVT:NASDAQ
Immunovant Inc
$38.45
+0.55%
(+0.21) 1D
Jun 26, 11:38:18 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMVT...
Open
$38.01
High
$38.60
Low
$37.51
Mkt. cap
7.88B
Avg. vol.
2.33M
Volume
212.60K
52-wk high
$39.28
52-wk low
$14.32
EPS
-$2.77
Beta
0.76
Shares outstanding
205.31M
No. of employees
315
Open
$38.01
High
$38.60
Low
$37.51
Mkt. cap
7.88B
Avg. vol.
2.33M
Volume
212.60K
52-wk high
$39.28
52-wk low
$14.32
EPS
-$2.77
Beta
0.76
Shares outstanding
205.31M
No. of employees
315
News stories
From sources across the web
About Immunovant Inc
CEO-
Employees315
Founded2018
Headquarters-
SectorBiotechnology
Websiteimmunovant.com
Analyst ratings
Based on 12 analysts giving stock ratings to IMVT in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for IMVT in the last 3 months.
Highest
Current $38.45
$66.00 (+71.65%)
Average
$46.33 (+20.49%)
Lowest
$30.00 (-21.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$66.00
+71.7%
05/29/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$47.00
+22.2%
05/26/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$62.00
+61.2%
05/26/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$40.00
+4%
05/26/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$49.00
+27.4%
05/25/2026
Danielle Brill
Truist Financial
Hold
Maintained
$30.00
-22%
05/22/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
$45.00
+17%
05/23/2026
Dina Ramadane
Bank of America Securities
Buy
Reiterated
$43.00
+11.8%
05/21/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$43.00
+11.8%
05/21/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$45.00
+17%
05/21/2026
Corinne Johnson
Goldman Sachs
Hold
Reiterated
$32.00
-16.8%
04/15/2026
Andy Chen
Wolfe Research
Buy
Maintained
$47.00
+22.2%
04/06/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$50.00
+30%
04/02/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$45.00
+17%
04/01/2026
William Pickering
Bernstein
Hold
Initiated
$28.00
-27.2%
03/20/2026
Leland Gershell
Oppenheimer
Buy
Maintained
$54.00
+40.4%
02/09/2026
Last report
May 20, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
-$0.73 / -$0.62
-18.09%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
101.20M
114.25M
98.92M
142.29M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.02M
17.51M
15.44M
17.27M
Operating expense
127.22M
131.76M
114.36M
159.55M
Total operating expenses
127.22M
131.76M
114.36M
159.55M
Operating income
-127.22M
-131.76M
-114.36M
-159.55M
Other non operating income
1.19M
250.00K
-54.00K
798.00K
EBT including unusual items
-119.70M
-125.91M
-109.08M
-150.70M
EBT excluding unusual items
-119.70M
-125.91M
-109.08M
-150.70M
Income tax expense
913.00K
594.00K
1.55M
-2.84M
Effective tax rate
-0.76%
-0.47%
-1.42%
1.89%
Other operating expenses
-
-
-
-
Net income
-120.61M
-126.50M
-110.64M
-147.86M
Net profit margin
-
-
-
-
Earnings per share
-0.71
-0.65
-0.54
-0.67
Interest and investment income
6.34M
5.60M
5.33M
8.06M
Interest expense
-
-
-
-
Net interest expenses
6.34M
5.60M
5.33M
8.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-127.12M
-131.66M
-114.26M
-159.46M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of IMVT
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer